DNA Therapeutics

DNA Therapeutics develops targeted drugs against resistant cancer with a lead IMP demonstrating good safety & antitumor activity in patients

  • Stage Product In Development
  • Industry Biotechnology
  • Location Évry, IDF, France
  • Currency EUR
  • Founded June 2006
  • Employees 8
  • Website dna-therapeutics.com

Company Summary

DNA Therapeutics is a spin-off of the Institut Curie, INSERM, CNRS, MNHN. It develops a new class of targeted drugs against resistant cancer based on a novel concept Dbait. Its lead DT01 has already shown antitumor activity with good safety & tolerance in patients (phase I/IIa). The ability of DT01 to improve the efficacy of existing cancer therapies without additional toxicity makes it a promising drug to address the unmet needs in many cancers.

Team

  • Jian-Sheng Sun
    Chief Executive Officer

    Co-founder, con-inventor, CEO since inception.
    Ph.D in Biophysics at UPMC Paris, entrepreneur training at HEC Paris.
    30 years in oligo therapeutics field, full professor, former lab head.
    Recipient of the Grand Prize of Life Science 2006 of French Senate, the Award of Best Innovative Entrepreneur in Health 2008 by French Angels in Health.

    Management team formed by experienced professionals, world class experts & key opinion leaders in onco

  • Patricia Noguiez-Hellin
    Manager of Pharmaceutical Development

  • Flavien Devun
    Manager of pharmaceutical & clinical affairs

  • Jian-Sheng Sun

Advisors

  • EGIP, Paris
    Lawyer
    Unconfirmed
    AVVENS, Lyon
    Accountant
    Unconfirmed

Previous Investors

  • SEFTI,
    Unconfirmed
    G1J Ile de France, Inserm Transfert Initiative,
    Unconfirmed
    business angels
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free